Portfolio Companies

Portfolio Companies

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

: (NASDAQ: FOLD)

Cranbury, NJ
Developing small molecule, orally active drugs to treat lysosomal storage disorders using pharmacological chaperones to selectively bind and "rescue" misfolded target proteins

: Baltimore, MD
Developing arginase inhibitors for vascular and pulmonary conditions

: Durham, NC
Developing novel peptide drug candidates to treat psychosis and pain using a proprietary amino acid analog substitution technology enabling rapid and efficient discovery

: Pittsboro, NC
Applying a lemna based manufacturing system to complex recombinant therapeutic production targeting infectious diseases, thrombolytics, and autoimmune diseases initially

: King of Prussia, PA
Applying a proprietary protein engineering platform with a modified form of transferring to enhance half life, efficacy, and safety of proteins, initially targeting diabetes
Acquired by Pfizer in February 2007

: Princeton, NJ
Identifying ratios of synergistic drug combinations in vitro and fixing ratios in liposomal drug carriers to remain true in vivo for the treatment of various cancers

: Philadelphia, PA
Using a platform, CB-CAPs (Cell-Bound Complement Activation Products) to develope an early identification and monitoring solution for autoimmune diseases

: Conshohocken, PA
Using Hepatocyte Directed Vesicles to delivery insulin for diabetes treatment

: (NASDAQ: DSCO)

Warrington, PA
Developing a synthetic lung surfactant to add lung development in premature infants

: Bedminster, NJ
Specialty pharma company focused on the acute care setting treating conditions in the cardiology, thrombolytics, and oncology supportive care therapeutic areas

: Berwyn, PA
Developing late stage cancer therapeutics. Eximias is now a wholly-owned subsidiary of YM named YM BioSciences USA
Acquired by YM Biosciences in May 2006

: West Conshohocken, PA
Targeting serotonin receptors to initiate apoptosis to treat multiple myeloma and psoriasis

: Morrisville, NC
Clinical stage company developing a novel, office-based medical device to treat dry eye syndrome

: Pittsburgh, PA
Specialty pharmaceutical distributor, focused on high-cost injectables and infusibles that require special handling and strict adherence to prescribed treatment protocols
Acquired by Walgreen Co. in July 2006

: Malvern, PA
Developing novel oncolytic viruses to treat cancer

: Malvern, PA
Developing and commercializing Transcranial Magnetic Stimulation, a noninvasive medical technology, to treat psychiatric and neurological disorders

: Bristol, PA
Development of a proprietary and patented drug/device technology delivering gaseous nitric oxide for the treatment of chronic wounds, skin infections and psoriasis

: Conshohocken, PA
Specialty pharma company developing innovative products for the treatment of neurological and psychiatric diseases

: Edison, NJ
Specialty pharmaceutical company focused on commercializing late-stage and approved assets

: New Haven, CT
Developing therapeutics and diagnostics based on Complement Factor H (CFH) research to treat for the dry form of age related macular degeneration (AMD) and membranoproliferative glomerulonephritis type II (MPGN-II)

: Pittsburgh, PA
Personalized diagnostics enabling customized and predictive treatment decisions for individual cancer patients

: Malvern, PA
Developing small molecule antibiotics to address increasing bacterial resistance and chronic or recurrent infections
Acquired by Novartis AG in July 2008

: Morrisville, NC
Developing antidote-controlled therapeutics via rational design of drug-antidote pairs using modified RNA-based aptamers to target antithrombotics initially

: South Orange, NJ
Commercializing consumer products for female sexual health, including lead product Zestra®

: Horsham, PA
Emerging growth services company revolutionizing the way pharmaceutical companies apply marketing information to their operations

: East Norriton, PA
Developing new human tissues and organs that are derived from a patient's own cells, initially treating spina bifida and spinal cord injury with the neo-bladder

: Malvern, PA
Developing novel, targeted drugs to treat cancer with Smac-mimetic candidates to regulate the apoptosis (programmed cell death) pathway

: Monmouth Jct., NJ
Developing an inhaled therapeutics to treat chronic respiratory infections

: Framingham, MA
Developing proprietary drug/device platform for the treatment of dermatological diseases

: Durham, NC
Developing unique small molecule therapeutics originating from its proprietary chemistry platform, initially targeting GI motility disorders